Announcements Trials
Browse Landscape

Phase

Phase NA 121Phase 2 6Phase 3 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Motor Activity 1Melanoma 1Carcinoma, Merkel Cell 1

Interventions

Magnetic Resonance Spectroscopy 26pembrolizumab 17Specimen Handling 17Radiotherapy 17Nivolumab 15Cyclophosphamide 14Temozolomide 11Biopsy 11Fluorodeoxyglucose F18 10fludarabine 9X-Rays 9Etoposide 7Bevacizumab 7Standard of Care 6Radiation 6Paclitaxel 6Dexamethasone 6Cisplatin 6Carboplatin 6Surgical Procedures, Operative 5Ipilimumab 5Doxorubicin 5Aspirin 5venetoclax 4olaparib 4fluciclovine F-18 4atezolizumab 4abemaciclib 4Vincristine 4Rituximab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Exercise × 1 year × Clear all
NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Active not recruiting
22 enrolled
Dermatologic

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡